School of Medicine
Showing 341-350 of 1,299 Results
-
Kevin Schulman
Professor of Medicine (Hospital Medicine), by courtesy, of Health Policy and of Operations, Information and Technology at the Graduate School of Business
BioDr. Schulman is a Professor of Medicine, and, by courtesy, Professor of Operations, Information and Technology at Stanford’s Graduate School of Business. He serves as Interim Division Co-Chief for the Division of Hospital Medicine at Stanford, and as an Associate Chair of the Department of Medicine. He is the Faculty Director of Stanford’s new applied master degree program, the Master of Science in Clinical Informatics Management program. He also serves as Deputy Director of the Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and has an appointment in the Department of Health Policy (by courtesy).
Dr. Schulman is a health economist/health services researcher working at the intersection of business, medicine and technology. With over 500 publications, he has had a broad impact on several areas of health policy (Scopus h-index=81). His research has appeared in the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is the editor-in-chief of Health Management, Policy and Innovation (www.HMPI.Org), and Senior Associate Editor of Health Service Research (HSR).
He is a graduate of Dartmouth College, the New York University School of Medicine, and The Wharton Health Care Management Program. He is an elected member of ASCI and AAP. -
Candice Schultz
Clinical Instructor (Affiliated), School of Medicine - Senior Associate Dean for Medical Student Education
Staff, Surgery - General SurgeryBioCandice Schultz, PA is a physician assistant at Stanford Health Care's Breast Cancer Program.
-
Liora Schultz
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
